Brandes Investment Partners LP Boosts Stock Holdings in LENSAR, Inc. (NASDAQ:LNSR)

Brandes Investment Partners LP lifted its position in LENSAR, Inc. (NASDAQ:LNSR) by 10.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 489,318 shares of the company’s stock after buying an additional 45,920 shares during the period. Brandes Investment Partners LP’s holdings in LENSAR were worth $4,375,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Evernest Financial Advisors LLC purchased a new position in shares of LENSAR in the 4th quarter worth approximately $174,000. Bailard Inc. purchased a new position in shares of LENSAR in the 4th quarter worth approximately $181,000. Atria Investments Inc grew its position in LENSAR by 28.2% during the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock worth $233,000 after purchasing an additional 5,729 shares during the last quarter. Essex Investment Management Co. LLC grew its position in LENSAR by 18.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after purchasing an additional 6,184 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after purchasing an additional 3,423 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.

LENSAR Trading Up 3.6 %

NASDAQ:LNSR opened at $15.13 on Friday. The company has a market cap of $178.37 million, a PE ratio of -10.36 and a beta of 0.62. LENSAR, Inc. has a twelve month low of $2.67 and a twelve month high of $16.40. The company’s 50 day moving average is $10.72 and its two-hundred day moving average is $7.78.

LENSAR (NASDAQ:LNSR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The business had revenue of $16.73 million for the quarter, compared to analyst estimates of $14.95 million.

Analyst Ratings Changes

Separately, Lake Street Capital boosted their target price on shares of LENSAR from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 28th.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.